LoneStar Heart Inc.
Addressing heart failure with an injectable biopolymer
This article was originally published in Start Up
Executive Summary
LoneStar Heart's injectable biopolymer Algisyl-LVR represents a new advanced HF treatment strategy based on a medically accepted principle that a reduction in muscle tension and wall stress of the dilated heart will improve its function. The company, which originally envisioned Algisyl-LVR as a carrier for targeted delivery of biologics, drugs, or stem cells, discovered in animal studies that use of the biopolymer by itself had a profound effect on improving the mechanics of the heart.
You may also be interested in...
Octave Biosciences Takes It Up Another Semitone With Michael J Fox Foundation Grant
The diagnostics company has secured $10m from the foundation to develop a biomarker test for Parkinson’s disease.
What’s Next? Five Things To Look Out For In December
Generics Bulletin previews the most noteworthy and anticipated events for December 2023.
Member States Want Action Over High-Risk IVDs And Eudamed Medical Device Database
After some 10 years of the implementation of the EU’s Medical Device and IVD Regulations being an annual agenda item at December Council of the EU meetings, the scale of problems remains the same.